14:09 , May 18, 2018 |  BC Week In Review  |  Company News

U of Birmingham spins out RA newco

University of Birmingham (Birmingham, U.K.) spun out newco Viatem Ltd. to develop rheumatoid arthritis therapies based on a peptide that plays a role in the recruitment of immune cells to inflamed tissues. The newco will...
23:06 , May 14, 2018 |  BC Extra  |  Company News

U of Birmingham spins out RA newco

University of Birmingham (Birmingham, U.K.) spun out newco Viatem Ltd. to develop rheumatoid arthritis therapies based on a peptide that plays a role in the recruitment of immune cells to inflamed tissues. The newco will...
23:07 , May 18, 2017 |  BC Innovations  |  Product R&D

Making cells compute

With efficiency in DNA engineering continuing to grow, and an increasing convergence between engineering and biology, synthetic biology -- in its “truest” form -- is coming within striking distance of translating preclinical proof of concept...
19:18 , Apr 7, 2017 |  BC Week In Review  |  Clinical News

BMS-986036: Ph II data

A double-blind, U.S. Phase II trial in 68 evaluable NASH patients with a hepatic fat fraction of ≥10% showed that once-daily 10 mg and once-weekly 20 mg subcutaneous BMS-986036 each met the primary endpoint of...
18:36 , Mar 24, 2017 |  BioCentury  |  Strategy

Connecting in Kyoto

While Novo Nordisk A/S is banking on its clinical pipeline and late-stage M&A to rejuvenate its P&L, a recent “innovation summit” with Japanese researchers shows the company hasn’t given up hunting for academic science. Novo...
22:30 , Mar 16, 2017 |  BC Innovations  |  Targets & Mechanisms

Bone appétit!

Last week’s Nature publication of a hormone secreted by bone that suppresses appetite and can curb weight gain not only adds to the emerging picture of bone as a player in the endocrine system but...
03:51 , Nov 19, 2016 |  BioCentury  |  Strategy

Adding on in fibrosis

Bristol-Myers Squibb Co. ’s deal to license worldwide rights to Nitto Denko Corp .’s antifibrotic siRNA therapy gives the pharma one of industry’s broadest fibrosis pipelines - and the ability to test multiple combinations. BMS...
07:00 , Oct 20, 2016 |  BC Innovations  |  Translation in Brief

Killer burn

A Cell Metabolism study argues a type of immune cell, dubbed invariant NK T (iNKT) cell, is responsible for the weight-lowering effects of glucagon-like peptide-1 receptor ( GLP-1R ; GLP1R ) agonists by increasing fat...
07:00 , Apr 11, 2016 |  BC Week In Review  |  Clinical News

Subcutaneous beloranib: Additional Phase III data

Additional data from the double-blind, U.S. Phase III bestPWS (ZAF-311) trial in 107 patients with Prader-Willi syndrome showed that twice-weekly 1.8 and 2.4 mg doses of subcutaneous beloranib each met the secondary endpoints of reducing...
08:00 , Mar 10, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Adiponectin (ADIPOQ)

Genitourinary disease INDICATION: Polycystic ovary syndrome (PCOS) Rat studies suggest promoting brown fat activity with ADIPOQ could help treat PCOS. In a rat model of PCOS, subcutaneous transplantation of brown fat increased estrous cycling, incidence...